ArticleAmerican journal of translational research2025
BASP1, targeted by miR-185-5p, promotes atherosclerosis via VSMC proliferation and inflammation.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the functional role and regulatory mechanisms of brain acid-soluble protein 1 (BASP1) in atherosclerosis (AS).
methodsqRT-PCR was performed to detect BASP1 and miR-185-5p expression in the serum of healthy subjects and AS patients. Human umbilical artery smooth muscle cells (HUASMCs) were exposed to oxidized low-density lipoprotein (ox-LDL) to induce an AS cell model. The target binding relationship between BASP1 and miR-185-5p was verified by luciferase reporter gene assay and qRT-PCR. The effects of BASP1 on ox-LDL-induced proliferation, apoptosis and inflammation were evaluated through a series of in vitro assays. Rescue experiments were conducted to analyze the functional regulation of miR-185-5p by BASP1.
resultsBASP1 expression was significantly elevated in the serum of AS patient and in ox-LDL-treated HUASMCs. Silencing BASP1 or overexpressing miR-185-5p reduced cell proliferation, apoptosis, inflammation, and adhesion molecule expression (vascular cellular adhesion molecule-1 (VCAM-1) and Intercellular adhesion molecule 1 (ICAM-1)). miR-185-5p directly targeted and negatively regulated BASP1. BASP1 overexpression partially reversed the effects of miR-185-5p mimics on ox-LDL-induced proliferation, apoptosis, inflammation, and adhesion molecule expression.
conclusionBASP1 may promote ox-LDL-induced proliferation and apoptosis in HUASMCs. The miR-185-5p/BASP1 molecular axis represents a promising target for the prevention and treatment of AS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.